TESARO Announces Fourth-Quarter 2015 Operating Results
U.S. commercial launch of VARUBI® (oral rolapitant) well underway Niraparib Phase 3 NOVA results expected in Q2 2016 are positioned to be the first data from a randomized, prospective Phase 3 trial of a PARP inhibitor New Drug Application (NDA) submission …